Cargando…
Current treatment protocol for COVID-19 in India
The whole world is now facing the battle against the severe and dangerous pandemic COVID-19, which is not only physically harming, but also mentally disturbing because of the unceasingly escalating number of affected patients and deaths globally. In India, the containment strategies constitute in id...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832705/ https://www.ncbi.nlm.nih.gov/pubmed/34766036 http://dx.doi.org/10.1016/j.sintl.2020.100013 |
_version_ | 1783641895591739392 |
---|---|
author | Sharma, Surbhi Basu, Soumen Shetti, Nagaraj P. Aminabhavi, Tejraj M. |
author_facet | Sharma, Surbhi Basu, Soumen Shetti, Nagaraj P. Aminabhavi, Tejraj M. |
author_sort | Sharma, Surbhi |
collection | PubMed |
description | The whole world is now facing the battle against the severe and dangerous pandemic COVID-19, which is not only physically harming, but also mentally disturbing because of the unceasingly escalating number of affected patients and deaths globally. In India, the containment strategies constitute in identifying, tracing-contacts, quarantine, social distancing, and following other health advisories. The current treatment protocols include real-time PCR test and Point-of-Care molecular diagnostic assays for its diagnosis; some states in India have begun the pool testing. Hydroxychloroquine (HCQ) is being recommended as chemoprophylaxis drug for asymptomatic healthcare personnel handling COVID-19 cases, frontline workers, and asymptomatic contacts of the confirmed cases, while hydroxychloroquine-azithromycin combination for patients with serious sickness. India has also launched ‘ArogyaSetu’ mobile-application for tracking the movements of the citizens and has also commenced convalescent plasma therapy to combat the deadly COVID-19. This timely article is a report on the current situation of COVID-19 in India. The discussion can throw light on the potential of a developing country such as India to deal with the pandemic and some of these can be helpful in adverse circumstances in the future. |
format | Online Article Text |
id | pubmed-7832705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78327052021-01-26 Current treatment protocol for COVID-19 in India Sharma, Surbhi Basu, Soumen Shetti, Nagaraj P. Aminabhavi, Tejraj M. Sensors International Article The whole world is now facing the battle against the severe and dangerous pandemic COVID-19, which is not only physically harming, but also mentally disturbing because of the unceasingly escalating number of affected patients and deaths globally. In India, the containment strategies constitute in identifying, tracing-contacts, quarantine, social distancing, and following other health advisories. The current treatment protocols include real-time PCR test and Point-of-Care molecular diagnostic assays for its diagnosis; some states in India have begun the pool testing. Hydroxychloroquine (HCQ) is being recommended as chemoprophylaxis drug for asymptomatic healthcare personnel handling COVID-19 cases, frontline workers, and asymptomatic contacts of the confirmed cases, while hydroxychloroquine-azithromycin combination for patients with serious sickness. India has also launched ‘ArogyaSetu’ mobile-application for tracking the movements of the citizens and has also commenced convalescent plasma therapy to combat the deadly COVID-19. This timely article is a report on the current situation of COVID-19 in India. The discussion can throw light on the potential of a developing country such as India to deal with the pandemic and some of these can be helpful in adverse circumstances in the future. The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. 2020 2020-06-01 /pmc/articles/PMC7832705/ /pubmed/34766036 http://dx.doi.org/10.1016/j.sintl.2020.100013 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Sharma, Surbhi Basu, Soumen Shetti, Nagaraj P. Aminabhavi, Tejraj M. Current treatment protocol for COVID-19 in India |
title | Current treatment protocol for COVID-19 in India |
title_full | Current treatment protocol for COVID-19 in India |
title_fullStr | Current treatment protocol for COVID-19 in India |
title_full_unstemmed | Current treatment protocol for COVID-19 in India |
title_short | Current treatment protocol for COVID-19 in India |
title_sort | current treatment protocol for covid-19 in india |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832705/ https://www.ncbi.nlm.nih.gov/pubmed/34766036 http://dx.doi.org/10.1016/j.sintl.2020.100013 |
work_keys_str_mv | AT sharmasurbhi currenttreatmentprotocolforcovid19inindia AT basusoumen currenttreatmentprotocolforcovid19inindia AT shettinagarajp currenttreatmentprotocolforcovid19inindia AT aminabhavitejrajm currenttreatmentprotocolforcovid19inindia |